Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518186

— · A

d9b560ba-b7e7-5a70-9faa-917b3c055d13

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
  • ANGIOGENESIS+0.510
  • ADIPOGENESIS+0.460
  • COAGULATION+0.410
  • COMPLEMENT+0.360
  • UV_RESPONSE_DN+0.360
  • MYOGENESIS+0.350
  • HYPOXIA+0.340
  • IL6_JAK_STAT3_SIGNALING+0.330
  • XENOBIOTIC_METABOLISM+0.330

Top 10 suppressed

  • MYC_TARGETS_V2-0.720
  • MYC_TARGETS_V1-0.580
  • E2F_TARGETS-0.400
  • UNFOLDED_PROTEIN_RESPONSE-0.390
  • G2M_CHECKPOINT-0.380
  • DNA_REPAIR-0.300
  • MTORC1_SIGNALING-0.300
  • INTERFERON_ALPHA_RESPONSE-0.220
  • WNT_BETA_CATENIN_SIGNALING-0.120
  • MITOTIC_SPINDLE-0.090

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2208941
melanoma-umap@29
——0.887
2SRR5088898
melanoma-umap@29
——0.880
3SRR8518203
breast-umap@18
—A0.876
4TCGA-38-4627-01A-01R-1206-07
lung-landscapes@6
—cohortA10.869
5TCGA-CN-6019-01A-11R-1686-07
head-neck@1
——0.869
6TCGA-CN-4740-01A-01R-1436-07
head-neck@1
——0.868
7TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.868
8TCGA-BH-A1FE-06A-11R-A213-07
breast-umap@18
—A0.862
9TCGA-D8-A1JU-01A-11R-A13Q-07
breast-umap@18
—A0.862
10MBCProject_0419_T2_RNA
breast-umap@18
—A0.858

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.530Inavolisib— uncovered
ANGIOGENESIS0.510Remibrutinib— uncovered
ADIPOGENESIS0.460Inavolisib— uncovered
COAGULATION0.410Binimetinib— uncovered
COMPLEMENT0.360Inavolisib— uncovered
UV_RESPONSE_DN0.360Inavolisib— uncovered
MYOGENESIS0.350Inavolisib— uncovered
HYPOXIA0.340Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.330Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.330Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
BILE_ACID_METABOLISM0.240Inavolisib— uncovered
FATTY_ACID_METABOLISM0.230Inavolisib— uncovered
APICAL_JUNCTION0.210Inavolisib— uncovered
HEME_METABOLISM0.210Temsirolimus— uncovered
IL2_STAT5_SIGNALING0.180Idelalisib— uncovered
HEDGEHOG_SIGNALING0.170Inavolisib— uncovered
TGF_BETA_SIGNALING0.160Inavolisib— uncovered